In vitro effect of schistosomicidal drugs on hepatic arylsulfatase B from the Schistosoma-infected mouse

Figures & data

Figure 1 SDS-PAGE of purified hepatic ASB from normal mouse. From left to right, lane 1: standard proteins; lane 2: purified enzyme.

Figure 2 Double reciprocal plots of the effect of substrate concentration on purified ASB from infected mouse in absence and presence of increasing concentrations of praziquantel (0–10 mM) from lower to upper lines, respectively.

Figure 3 Double reciprocal plot of the effect of substrate concentration on purified ASB from Schistosoma-infected mouse in absence and presence of increasing concentrations of commiphora extract (0–10 mg/ml) from upper to lower lines, respectively.

Table I.  Immunoinhibition of ASB by ASB-antiserum. The hepatic enzyme from the normal and infected mouse was immunoprecipitated by different volumes of ASB antiserum, incubated and assayed at 37°C.

	ASB Activity*
Antiserum (μl)	Control	Infected
20	4.80	5.29
30	4.68	5.11
40	4.22	5.31
50	4.56	5.20
60	4.54	5.40
80	4.80	5.42
100	4.90	5.44

* The enzyme activity is expressed as (nmol/ml/h) × 10³.

Figure 4 (a) Effect of some ligands on binding of ASB antiserum to the purified ASB from control mice. Binding was measured by ELISA and expressed as Absorbance at 450 nm. Data are average of six measurements. C: ASB antiserum for ASB from control mouse; I: ASB antiserum for ASB from infected mouse. (b) Effect of some ligands on binding of ASB antiserum to the purified ASB from Schistosoma-infected mice. Binding was measured by ELISA and expressed as Absorbance at 450 nm. Data are average of six measurements. C: ASB antiserum for ASB from control mouse; I: ASB antiserum for ASB from infected mouse.